Abcam (supplier of life science research tools) has signed a memorandum of understanding (MoU) with Shuwen Biotech (company focused on the development and commercialisation of companion diagnostics — CDx) to establish global alliance for CDx kit development.
Sign agreement
As per the terms of the agreement, the companies will jointly leverage their capabilities in producing high-quality antibodies and CDx kit development and commercialisation to better serve the needs of the pharma industry.
“Shuwen has a long-standing reputation amongst pharmaceutical companies for companion diagnostic kit development and central lab testing, and Abcam is a recognized leader in quality antibody development. This alliance will undoubtedly further strengthen Shuwen’s capabilities in developing quality companion diagnostic kits especially immunoassay kits,” explained Jay Z. Zhang, Shuwen’s chief executive officer and chairman. “We have seen continuous advances at all levels in personalized medicine over the past few years and these can only continue through innovative technologies like those that will be born out of joint efforts between Shuwen and Abcam.”
John Baker, Abcam’s SVP Portfolio and Business Development commented: “Abcam is pleased to establish this long-term collaborative strategic partnership, combining our unique capabilities to develop sensitive, highly-specific and validated antibodies with Shuwen’s proven track-record in the CDx space. Our work with Shuwen will focus on developing efficient and comprehensive solutions to advance clinical diagnostics and precision medicine, faster.”